1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016

Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 46 pages

Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss
- The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects
- The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acute Sensorineural Hearing Loss - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Sensorineural Hearing Loss Overview 6
Therapeutics Development 7
Pipeline Products for Acute Sensorineural Hearing Loss - Overview 7
Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies 8
Acute Sensorineural Hearing Loss - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Acute Sensorineural Hearing Loss - Products under Development by Companies 12
Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development 13
Nordmark Arzneimittel GmbH and Co. KG 13
Orbis Biosciences, Inc. 14
Otologic Pharmaceutics, Inc. 15
Xigen SA 16
Acute Sensorineural Hearing Loss - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
(acetylcysteine + disufenton sodium) - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ancrod - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
betamethasone valerate ER - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Otopotin - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Otostem - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Small Molecules for Sensorineural Hearing Loss - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
XG-102 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Acute Sensorineural Hearing Loss - Recent Pipeline Updates 37
Acute Sensorineural Hearing Loss - Dormant Projects 40
Acute Sensorineural Hearing Loss - Product Development Milestones 41
Featured News and Press Releases 41
Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss 41
Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery 41
May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111 42
Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders 42
Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 43
Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for Acute Sensorineural Hearing Loss, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Acute Sensorineural Hearing Loss - Pipeline by Nordmark Arzneimittel GmbH and Co. KG, H1 2016 13
Acute Sensorineural Hearing Loss - Pipeline by Orbis Biosciences, Inc., H1 2016 14
Acute Sensorineural Hearing Loss - Pipeline by Otologic Pharmaceutics, Inc., H1 2016 15
Acute Sensorineural Hearing Loss - Pipeline by Xigen SA, H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Assessment by Combination Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Acute Sensorineural Hearing Loss Therapeutics - Recent Pipeline Updates, H1 2016 37
Acute Sensorineural Hearing Loss - Dormant Projects, H1 2016 40

List of Figures
Number of Products under Development for Acute Sensorineural Hearing Loss, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 19
Number of Products by Stage and Targets, H1 2016 19
Number of Products by Mechanism of Actions, H1 2016 21
Number of Products by Stage and Mechanism of Actions, H1 2016 21
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histamine H4 Recepto ...

Tinnitus - Pipeline Review, H2 2016

Tinnitus - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Tinnitus - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tinnitus - Pipeline Review, H2 2016’, provides an overview of the Tinnitus pipeline landscape. The report provides comprehensive ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.